Physician- and patient-reported perspectives on myasthenia gravis in Europe: a real-world survey

• Published in: Orphanet journal of rare diseases 2023-06, Vol.18 (1), p.169-169, Article 169
• Main Authors: Mahic, Milada, Bozorg, Ali, DeCourcy, Jonathan, Golden, Keisha, Gibson, Gregor, Taylor, Christian, Scowcroft, Anna
• Format: Article
• Language: English
• Subjects: Acetylcholinesterase; Care and treatment; Cholinesterase inhibitors; Chronic fatigue syndrome; Clinical medicine; Clinical trials; Comorbidity; Demographics; Diagnosis; Diplopia; Disease management; Dosage and administration; Enzyme inhibitors; Europe; Family physicians; Genetic aspects; HCRU; Health care; Humans; Immunoglobulins; Kinases; Medical care; Medical diagnosis; Medical research; Medical treatment; Middle Aged; Myasthenia gravis; Myasthenia Gravis - drug therapy; Neuromuscular diseases; Neuromuscular junctions; Patient Reported Outcome Measures; Patients; Physicians; Practice; Productivity; Quality management; Quality of Life; Questionnaires; Rare diseases; Real-world data; Resource utilization; Surveys; Symptoms
• ISSN: 1750-1172; 1750-1172
• DOI: 10.1186/s13023-023-02727-0

Myasthenia gravis (MG) is a rare, chronic, debilitating, unpredictable, and potentially life-threatening neuromuscular disease. There is a lack of real-world data on disease management that could be used to further understand and address unmet patient needs and burden. We aimed to provide comprehensive real-world insights in the management of MG in five European countries. Data were collected using the Adelphi Real World Disease Specific Programme™ in MG, a point-in-time survey of physicians and their patients with MG in France, Germany, Italy, Spain, and the United Kingdom (UK). Physician- and patient-reported clinical data were collected, including demographics, comorbidities, symptoms, disease history, treatments, healthcare resource utilization (HCRU), and quality of life outcomes. In total, 144 physicians completed 778 patient record forms from March to July 2020 in the UK, and from June to September 2020 in France, Germany, Italy and Spain. Mean patient age at symptom onset was 47.7 years, with a mean time from symptom onset to diagnosis of 332.4 days (10.97 months). At diagnosis, 65.3% of patients were classified as Myasthenia Gravis Foundation of America Class II or above. Mean number of symptoms reported at diagnosis per patient was five, with ocular myasthenia reported in at least 50% of patients. At time of survey completion, the mean number of symptoms reported per patient was five and ocular myasthenia and ptosis were each still present in more than 50% of patients. Acetylcholinesterase inhibitors were the most commonly prescribed chronic treatments in all countries. Of 657 patients treated with chronic treatment at the time of the survey, 62% continued to experience moderate-to-severe symptoms. On average, 3.1 healthcare professionals (HCPs) were involved in patient management, 6.2 consultations were made per patient with any HCP over the last 12 months, and 178 (22.9%) patients were hospitalized in the last 12 months. Overall, HCRU and disease management were similar across all countries. Our findings demonstrated the high burden of MG despite current treatment options for patients with MG.